Senior Vice President of Corporate Strategy, Development and M&A
Steve Mermelstein joined SomaLogic as Senior Vice President of Corporate Strategy, Development and M&A in November 2021, bringing with him extensive advisory and execution expertise focused on the life sciences sector, particularly tools and diagnostics, medical devices, and biopharma. He has more than 25 years of experience providing strategic and corporate finance advisory to senior management teams and boards of directors, executing a broad range of corporate transactions, including M&A, growth equity investments, recapitalizations, out-licensing and joint ventures.
Mr. Mermelstein most recently was Vice President of Strategy & Corporate Development at Agilent Technologies, where he led the M&A, Integration, and Market Analysis teams. Prior to that, he was Managing Director at Covington Associates, where he advised institutional-backed and middle-market companies in the life sciences sector. Prior to that he was a Managing Director at Huron Consulting Group, where he headed Huron Transaction Advisory LLC’s life sciences investment banking practice. Previously, he was a Director at Wasserstein Perella & Co., where he was responsible for Private Equity and M&A advisory across various industries. Mr. Mermelstein started his career at JPMorgan Chase & Co., where he specialized in M&A advisory and private equity investing through Chase Capital.
Mr. Mermelstein received a Bachelor of Arts in Government from Dartmouth College and an Executive MBA in Finance from New York University’s Stern School of Business.